Hematology

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
2215-CL-0301A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 MutationLeber, Dr BrianOpenNCT02421939
MEDALISTA Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536-MDS-001) Versus Placebo for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects with Ring Sideroblasts Who Require Red Blood Cell Transfusions (MEDALIST)Leber, Dr BrianOpenNCT02631070
M15-531A Randomized Phase 2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)Leber, Dr BrianOpenNCT02942290
AZA-MDS-003A phase 3, multicentre, randomized, double-blind study to compare with efficacy and safety of oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with red blood cell transfusion-dependent anemia and thrombocytopenia due to IPSS lower-risk myelodysplatic syndromesLeber, Dr BrianOpenNCT01566695
INSPIREA Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating AgentLeber, Dr BrianOpenNCT02562443
OZM-056Treatment-free Remission Accomplished with Dasatinib in Patients with CMLLeber, Dr BrianOpenNCT02268370
ASTRAL 3A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating AgentsLeber, Dr BrianOpenNCT02907359
M15-550Open-label, single arm, phase 3b, multi-center study evaluating the efficacy of Venetoclax (ABT-199) in relapsed/refractory subjects with chronic lymphocytic leukemia (CLL) including those with the 17p deletion or TP53 mutation OR those who are refractory or intolerant to B-cell receptor inhibitorsLeber, Dr BrianOpenNCT02756611
WO29519A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)Leber, Dr BrianOpenNCT02545283
LY.17A MULTI-STAGE RANDOMIZED PHASE II STUDY OF NOVEL COMBINATION THERAPY IN THE TREATMENT OF RELAPSED AND REFRACTORY AGGRESSIVE B-CELL LYMPHOMAFraser, Dr GraemeOn holdNCT02436707
Download PDF